Brentuximab vedotin, CAS 914088-09-8

Product Description: Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19./[2]Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65.

CAS Number: 914088-09-8

Molecular Weight: 153000 (average)

Compound Purity: 98.00

Research Area: Cancer

Solubility: H2O

Target: Antibody-Drug Conjugates (ADCs);Apoptosis;TNF Receptor

• Artikelnummer: MEXHY-P99107-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99107-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK